Los Angeles Capital Management LLC Acquires New Position in Avantor, Inc. (NYSE:AVTR)

Los Angeles Capital Management LLC acquired a new stake in shares of Avantor, Inc. (NYSE:AVTR) in the third quarter, Holdings Channel reports. The firm acquired 16,645 shares of the company’s stock, valued at approximately $431,000.

Other large investors have also modified their holdings of the company. Versant Capital Management Inc grew its position in shares of Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after buying an additional 1,102 shares during the last quarter. Blue Trust Inc. grew its position in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after purchasing an additional 1,391 shares during the last quarter. UMB Bank n.a. purchased a new stake in Avantor during the 3rd quarter worth approximately $49,000. Nisa Investment Advisors LLC grew its position in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after purchasing an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AVTR shares. Stifel Nicolaus boosted their target price on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Wells Fargo & Company decreased their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Barclays decreased their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Royal Bank of Canada restated an “outperform” rating and set a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. Finally, UBS Group decreased their price objective on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Insider Activity

In other news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now owns 29,544 shares in the company, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company’s stock.

Avantor Price Performance

Shares of AVTR opened at $20.74 on Monday. Avantor, Inc. has a 1-year low of $19.11 and a 1-year high of $28.00. The stock has a market cap of $14.12 billion, a PE ratio of 45.09, a P/E/G ratio of 2.51 and a beta of 1.35. The firm has a 50-day simple moving average of $24.52 and a two-hundred day simple moving average of $24.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.